

NEO, eVolve1 & OLALA Summary

Study Title	NCT Number	# of Patients Enrolled	Pending Sites
<u>OZM-058</u> A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer The NEO trial	NCT#: 02489006	Arm A (Chemotherapy) = 0 Arm B (Olaparib) = 0	<ol style="list-style-type: none"> 1. Tom Baker CC (end-Nov 2016) 2. Notre Dame Hospital (CHUM) (Dec 2016) 3. McGill University Health Centre (Q1 2017) 4. Universitaire Ziekenhuizen Leuven (Q1 2017) 5. Auckland Hospital (Q1 2017)
<u>OZM-060</u> e-Volve 1 trial: A proof of concept, multi-centre, clinical trial of the combination cediranib-olaparib at the time of disease progression on PARP inhibitor in ovarian cancer.	NCT#: 02681237	Cohort A (Plat Sensitive) = 8 Cohort B (Plat Resistant) = 3 Cohort C (Exploratory) = 1	<ol style="list-style-type: none"> 1. Notre Dame Hospital (CHUM) (Q1 2017) 2. Vall d'Hebron Research Institute (Q1 2017)
<u>OZM-061</u> Olala Trial: A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours	NCT#:02489058	Long Term Responders = 5 Short Term Responders = 7	<ol style="list-style-type: none"> 1. BCCA (Dec 2016) 2. Edinburgh Cancer Research Centre (Q1 2017) 3. The Royal Marsden (Q1 2017)